

**DECLARATION FOR UTILITY OR DESIGN
PATENT APPLICATION (37 CFR 1.63)**

Attorney Docket No.: 2132.007
Inventor Name: Jackowski et al
COMPLETE IF KNOWN
Application No:
Filing Date:
Group Art Unit:
Examiner Name:

☒ Decl. Sub. w/Initial Filing
☐ Decl. Sub. after Initial Filing (surcharge (37 CFR 1.15 (e)))

As a below named inventor, I hereby declare that:

My residence, post office addr., and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**PROCESS FOR DIAGNOSIS OF PHYSIOLOGICAL CONDITIONS BY
CHARACTERIZATION OF PROTEOMIC MATERIALS**

the specification which
_____ is attached hereto OR
_____ was filed on _____ As United States Application No. or PCT Intl.
Appln. No. _____ and was amended on _____ (if
applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN NUMBERS:	COUNTRY:	FOREIGN FILING DATE:	PRIORITY NOT CLAIMED:	CERTIFIED COPY Yes No
			_____	_____
			_____	_____
			_____	_____

Additional foreign appln. nos. are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

APPLICATION NUMBER(s):

FILING DATE:

_____ Addnl. provisional appln.
Nos. are listed on a
Supplementary priority data
Sheet PTO/SB/02B attached.

DECLARATION - UTILITY or DESIGN PATENT APPLICATION

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. PARENT APPLICATION
or PCT NUMBER:

PARENT FILING DATE:

PARENT PATENT NO:
(if applicable)

Additional U.S. or PCT international appln.nos. are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: X Customer No: 21917 PLACE CUSTOMER No.
BAR CODE LABEL HERE

OR

Registered practitioner(s) name/registration no. listed below.

NAME:	REGISTRATION NO:	NAME:	REGISTRATION NO:
Michael A. Slavin	34,016	Joe Beckman	45,529
Ferris H. Lander	43,377		
C. Fred Rosenbaum	27,110		

DIRECT ALL CORRESPONDENCE TO: Customer Number OR
Or Bar Code Label Correspondence address below

NAME: McHale & Slavin, P.A.
ADDRESS: 4440 PGA Blvd.,
ADDRESS: Suite 402
CITY: Palm Beach Gardens STATE: FL ZIP: 33410
COUNTRY: U.S. TELEPHONE: (561) 625-6575 FAX: (561) 625-6572

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 17 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR: A Petition has been filed for this unsigned inv.

GIVEN NAME (first and middle [if any]):

FAMILY NAME OR SURNAME:

George

Jackowski

Inventor's signature: _____ Date: _____

Residence: 11725 Keele Street R1

City: Kettleby State: ONTARIO LOG 1J0 Country: CANADA Citizenship: Canadian

Post Office Address: 11715 Keele St., R1, Kettleby, Ontario LOG 1J0, CANADA

Additional inventors are being named on the _____ Supplemental additional inventor(s)
Page 2 of 3) sheet(s) PTO/SB/02A attached hereto.

NAME OF SECOND INVENTOR: _____ A Petition has been filed for this unsigned inv.
GIVEN NAME (first and middle [if any]): _____ **FAMILY NAME OR SURNAME:** _____

Brad Thatcher, PhD

Inventor's signature: _____ Date: _____

Residence: 12 Beaverdale Road,

City: Toronto State: ONTARIO M8Y 3Y4 Country: CANADA Citizenship: Canadian

Post Office Address: 12 Beaverdale Road, Toronto Ontario M8Y 3Y4, CANADA

NAME OF THIRD INVENTOR: A Petition has been filed for this unsigned inv.

GIVEN NAME (first and middle [if any]): FAMILY NAME OR SURNAME:

John Marshall, PhD

Inventor's signature: _____ Date: _____

Residence: 95 Parkside Drive

City: Toronto State: ONTARIO M6R 2V3 Country: CANADA Citizenship: Canadian

Post Office Address: 95 Parkside Drive, Toronto Ontario M6R 2V3, CANADA

NAME OF FOURTH INVENTOR: A Petition has been filed for this unsigned inv.

GIVEN NAME (first and middle [if any]): _____ FAMILY NAME OR SURNAME: _____

Jason Yantha, BSc

Inventor's signature: _____ Date: _____

Residence: 44 St. Joseph Street, Apt. 2102

City: Toronto State: ONTARIO M4Y 2W4 Country: CANADA Citizenship: Canadian

Post Office Address: 44 St. Joseph Street, Apt. 2102 Ontario M4Y 2W4, CANADA

NAME OF FIFTH INVENTOR: A Petition has been filed for this unsigned inv.

GIVEN NAME (first and middle [if any]): _____ FAMILY NAME OR SURNAME: _____

Tammy Vrees, BSc

Inventor's signature: _____ Date: _____

Residence: 215 Bronte Road

City: Oakville State: ONTARIO L6L 3C5 Country: CANADA Citizenship: Canadian

Post Office Address: 215 Bronte Road, Oakville Ontario L6L 3C5, CANADA

TABLE 40 APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 07	M	65	MI, Hx of arthritis,	MI	1020	Alpha Fibrinogen	(G)DFLAEGGGVR(G)
HNS-SJ28				MI	1020	Alpha Fibrinogen	(G)DFLAEGGGVR(G)
HNS-SJ33				MI	1020	Alpha Fibrinogen	(G)DFLAEGGGVR(G)
SJ CON 06	F	77		MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 17	M	58	MI	MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 19	M	52	Acute MI, SK???	MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
SJ CON 21	M	65	Non-Q wave MI, Hx HTN	MI	1077	Alpha Fibrinogen	(E)GDFLAEGGGVR(G)
HNS-SJ28							
SJ CON 05	F	67	Rectal bleed, Asthma, NIDDM	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAAAA(-)
SJ CON 06	F	77	MI, NIDDM	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAAAA(-)
TWH-039	M	62	A.fib, Diabetes, smoker, HTN	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAAAA(-)
184-988	M	73		Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAAAA(-)
TWH-039	M	62	A.fib, Diabetes, smoker, HTN	Type II Diabetes	1097	Apolipoprotein	(D)PEVRPTSAAAA(-)
184-988							
SJ CON 01	M	82		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 05	F	67		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 06	F	77		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 09	M	80		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 07	M	65		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 10	F	50		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 14	F	65		Renal Failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 13	F	80	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1206	Alpha Fibrinogen	(G)EGDFLAEGGGVR(G)
SJ CON 06	F	77		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 07	M	65	GE (gastroesophageal) reflux	MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 10	F	50	Inferior MI, Hiatal Hernia	MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 14	F	65	MI, NIDDM	MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 17	M	58		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 19	M	52		MI	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 21	M	65		MI	1211	Complement C3f	(H)RIHWESASLL(R)
HNS-SJ22							
HNS-SJ28							
HNS-SJ33							
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used tPA	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1211	Complement C3f	(H)RIHWESASLL(R)

FOUO DE 91890 APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
23604 - KKB	M	61	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1211	Complement C3f	(H)RIHWESASLL(R)
SJ CON 06	F	77		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 07	M	65		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 10	F	50	Hemodialysis	MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 14	F	65	hemodialysis	MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 17	M	58		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 19	M	52		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 21	M	65		MI	1348	Complement C3f	(T)HRIHWESASLL(R)
HNS-SJ22				MI	1348	Complement C3f	(T)HRIHWESASLL(R)
HNS-SJ28				MI	1348	Complement C3f	(T)HRIHWESASLL(R)
HNS-SJ33				MI	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used iPA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)

FOOTNOTES APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
CJ-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CJ-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CJ-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
SJ CON 01	M	82		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 05	F	67		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 06	F	77		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 06	F	77		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 09	M	80		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 07	M	65		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 07	M	65		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 10	F	50		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 10	F	50		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 14	F	65		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 14	F	65		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 17	M	58		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 19	M	52		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 21	M	65		MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ22				MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ28				MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ33				MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)

APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 11	M	68	Unstable angina, hemosdialysis	Renal failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 13	F	80	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23421 - FB	M	59	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
22813 - CL	F	66	STAGE 4	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23130 - ER	M	51	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23105 - FC	M	64	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23116 - FC	M	59	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
20414 - EYG	F	76	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23130 - ER	M	51	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23134 - FC	M	62	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
20102 - EAB	M	70	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
SJ CON 06	F	77		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 07	M	65		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 10	F	50		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 14	F	65		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 17	M	58		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 19	M	52		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 21	M	65		MI	1449	Complement C3f	(I)THRIHWESASLL(R)
HNS-SJ22				MI	1449	Complement C3f	(I)THRIHWESASLL(R)
HNS-SJ28				MI	1449	Complement C3f	(I)THRIHWESASLL(R)
HNS-SJ33				MI	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used tPA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)

Photo: JEE34300 APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
22703 - MMS	F	67	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22813 - CL	F	66	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23130 - ER	M	51	STAGE 4	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 01	M	82	STAGE 3	CHF	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 05	F	67		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 06	F	77		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 09	M	80		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 07	M	65		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 10	F	50		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 14	F	65		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 13	F	80	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-12	F	44	ICH	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 07	M	65		MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 10	F	50		MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
HNS-SJ22				MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 01	M	82		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 05	F	67		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 06	F	77		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 09	M	80		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)

APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 07	M	65		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 10	F	50		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 14	F	65		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 04	M	66	Unstable angina, hemodialysis	Renal failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 11	M	68	Unstable angina, hemodialysis	Renal failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 13	F	80	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1521	Serum Albumin	(D)PNHFRPAGLPEKY(-)
SJ CON 10	F	50		MI	1525	Serum Amyloid A	(D)PNHFRPAGLPEKY(-)
HNS-SJ22				MI	1525	Serum Amyloid A	(D)PNHFRPAGLPEKY(-)
HNS-SJ28				MI	1525	Serum Amyloid A	(T)ADSGEGDFLAEGGV(R)(G)
HNS-SJ22				MI	1536	Alpha Fibrinogen	(K)ITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 19	M	52		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 21	M	65		MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
HNS-SJ22				MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
HNS-SJ33				MI	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1562	Complement C3f	(K)ITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1616	Complement C3f	(K)ITHRIHWESASLL(R)

TABLE 34 APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 07	M	65		MI	1616	Complement C3f	
SJ CON 10	F	50		MI	1616	Complement C3f	
SJ CON 14	F	65		MI	1616	Complement C3f	
SJ CON 17	M	58		MI	1616	Complement C3f	
SJ CON 19	M	52		MI	1616	Complement C3f	
SJ CON 21	M	65		MI	1616	Complement C3f	
HNS-SJ22				MI	1616	Complement C3f	
HNS-SJ28				MI	1616	Complement C3f	
HNS-SJ33				MI	1690	Complement C3f	
SJ CON 06	F	77		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-12	F	44		Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used tPA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)

TODAY'S DISEASES APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
SJ CON 01	M	82	NIDDM, CHF, Hypothalemia??	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 01	M	82	patient died of CA Dec. 22/98	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 05	F	67	hemodialysis	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 06	F	77	hemodialysis	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 09	M	80	NIDDM, HTN, Rio?? Angina	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002	M	81		Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-009	M	76	Aphasia, Rt hemiparalysis,	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)

TOEHO" DEE94360

APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
22006 - MM	F	75	STAGE 4	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20102 - EAB	M	70	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002	M	81		Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH -009	M	76	Aphasia, Rt hemiparalysis,	Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-002				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH -009				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-024				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-039				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
743-450				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
184-988				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
734-989				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
SJ CON 01	M	82		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 06	F	77		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 06	F	77		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 09	M	80	Hx of prostate CA, hemodialysis	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-002	M	81		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH -009	M	76	Complete hemianopia, smoker	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-024	M	63	Stroke, PM Hx, NIDDM, incr BP	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-039	M	62		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
184-988	M	73	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
734-989	M	65	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 10	F	50		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 14	F	65		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 17	M	58		MI	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)

FOUO DECLASSIFIED APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 19	M	52		MI	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
SJ CON 21	M	65		MI	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
HNS-SJ22				MI	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
HNS-SJ28				MI	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
HNS-SJ33				MI	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-69	F	69	ICH, secondary to AVM	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-12	F	44	ICH	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-15	F	54	Acute CVA, Basal ganglia	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-10	M	66	HTN, ICH right thalamic	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-14	M	50	HTN, acute CVA	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-16	F	76	HTN, ICH (cerebellar vermis)	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-18	M	72	HTN, previous CVA, CVA (R MCA) used IPA	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-19	M	47	CVA, transfer to VA	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-28	M	55	HTN, ICH	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-30	M	56	HTN, ICH	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-33	M	72	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-37	M	72	HTN, acute CVA (R subcortical)	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-38	F	67	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-60	M	64	HTN, Prior CVA, ICH (R thalamic hemorrhage)	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-66	M	49	HTN, Prior CVA, CVA	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
CU-75	M	43	HTN, Prior CVA, ICH	Stroke-ICH	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23604 - KKB	M	61	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23707 - KL	F	65	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
22703 - MMS	F	67	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
20206 - MM	F	75	STAGE 4	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
22103 - GM	F	77	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
21813 - GR	F	65	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23402 - HM	M	67	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
20208 - HIF	M	79	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
22803 - HB	M	60	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23616 - JGK	M	43	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23421 - FB	M	59	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
22813 - CL	F	66	STAGE 4	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23105 - FC	M	64	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23116 - FC	M	59	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
20414 - EYG	F	76	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23130 - ER	M	51	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)
23134 - FC	M	62	STAGE 3	CHF	1865	Complement C3f	(+SSKITHRIHWESASLL(R)

Table 000000 APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
20102 - EAB	M	70	STAGE 3	CHF	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-002				Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-009			Complete hemianopia, smoker	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-024	M	63	Stroke, PM Hx, NIDDM, incr BP	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-039				Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
184-988	M	73	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
734-989	M	65	NIDDM	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 07	M	65		MI	1896	Complement C4A	(R)NGFKSHALQLNNRQIR(G)
SJ CON 17	M	58		MI	1896	Complement C4A	(R)NGFKSHALQLNNRQIR(G)
HNS-SJ22				MI	1896	Complement C4A	(R)NGFKSHALQLNNRQIR(G)
TWH-002				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
TWH-009				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
TWH-024				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
TWH-039				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
743-450				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
184-988				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
734-989				Type II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASLL(-)
SJ CON 01	M	82		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 06	F	77		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 06	F	77		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 09	M	80		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-002	M	81		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-009	M	76		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-024	M	63		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
TWH-039	M	62		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
184-988	M	73		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
734-989	M	65		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 07	M	65		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 10	F	50		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 14	F	65		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 17	M	58		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 19	M	52		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 21	M	65		MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
HNS-SJ22				MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
HNS-SJ28				MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
HNS-SJ33				MI	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23604 - KKB	M	61	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23707 - KL	F	65	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22703 - MMS	F	67	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20206 - MM	F	75	STAGE 4	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22103 - GM	F	77	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)

TOGETHER APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
21813 - GR	F	65	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23008 - GFB	M	67	STAGE3 - DEAD	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23402 - HM	M	67	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
20208 - HIF	M	79	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
22803 - HB	M	60	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23616 - JGK	M	43	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
20803 - EW	M	45	Acute MI - STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23421 - FB	M	59	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
22813 - CL	F	66	STAGE 4	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23130 - ER	M	51	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23105 - FC	M	64	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23116 - FC	M	59	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
20414 - EYG	F	76	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23130 - ER	M	51	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23134 - FC	M	62	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
20102 - EAB	M	70	STAGE 3	CHF	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
TWH-002				Type II Diabetes	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
TWH-009				Type II Diabetes	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
TWH-024				Type II Diabetes	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
TWH-039				Type II Diabetes	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
184-988				Type II Diabetes	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
734-989				Type II Diabetes	2021	Complement C3f	(+SSKITHRIHWESASLLR(-)
23604 - KKB	M	61	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23707 - KL	F	65	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22703 - MMS	F	67	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20206 - MM	F	75	STAGE 4	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22103 - GM	F	77	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
21813 - GR	F	65	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23008 - GFB	M	67	STAGE3 - DEAD	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23402 - HM	M	67	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20208 - HIF	M	79	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22803 - HB	M	60	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23616 - JGK	M	43	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20803 - EW	M	45	Acute MI - STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23421 - FB	M	59	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
22813 - CL	F	66	STAGE 4	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23130 - ER	M	51	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23105 - FC	M	64	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23116 - FC	M	59	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20414 - EYG	F	76	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23130 - ER	M	51	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
23134 - FC	M	62	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20102 - EAB	M	70	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR

Food "Defect" APPENDIX A

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
23134 - FC	M	62	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20102 - EAB	M	70	STAGE 3	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
3111898	M	?	Insulin Resistance	Insulin Resistance	2267	Apolipoprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
112698	F	?	Insulin Resistance	Insulin Resistance	2267	Apolipoprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
5124698	F	?	Insulin Resistance	Insulin Resistance	2267	Apolipoprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
3111898	M	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
42698	M	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
112698	F	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
6101600	F	?	Insulin Resistance	Insulin Resistance	2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
5124698	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLA(F)
3111898	M	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLA(F)
42698	M	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLA(F)
112698	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLA(F)
6101600	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLA(F)
5124698	F	?	Insulin Resistance	Insulin Resistance	2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLA(F)